Categories
Health

How Trump’s insurance policies might have an effect on buyers in these Eight market sectors

President-elect Donald Trump at a viewing of a test-flight launch of the SpaceX Starship rocket in Brownsville, Texas, Nov. 19, 2024.

Brandon Bell | Getty Images News | Getty Images

As Inauguration Day nears, investors are trying to unravel what booms or busts lay ahead under President-elect Donald Trump.

Trump’s campaign promises — from tariffs to mass deportations, tax cuts and deregulation — and his picks to lead federal agencies suggest both risks and rewards for various investment sectors, according to market experts.  

Republican control of both chambers of Congress may grant Trump greater leeway to enact his pledges, experts said. However, their scope and timing is far from clear.

More from FA Playbook:

Here’s a look at other stories impacting the financial advisor business.

“There’s so much uncertainty right now,” said Jeremy Goldberg, a certified financial planner, portfolio manager and research analyst at Professional Advisory Services, which ranked No. 37 on CNBC’s annual Financial Advisor 100 list.

“I wouldn’t be making large bets one way or another,” Goldberg said.

Sectors often fare differently than expected

Past market results show why it’s difficult to predict the sectors that may win or lose under a new president, according to Larry Adam, chief investment officer at Raymond James.

When Trump was elected in 2016, financials, industrials and energy outperformed the S&P 500 in the first week. However, for the remaining three years and 51 weeks, those same sectors significantly underperformed, Adam said.

“The market is known to have these knee-jerk reactions trying to anticipate where things go very quickly, but they don’t necessarily last,” Adam said.

What’s more, sectors that are expected to do well or badly based on a president’s policies have sometimes gone the opposite way, according to Adam.

For example, the energy sector was down by 8.4% during Trump’s first administration, despite deregulation, record oil production and a rise in oil prices. Yet the energy sector climbed 22.9% under Biden as of Nov. 19, despite the administration’s push for renewables and sustainability.

For that reason, Raymond James ranks politics eighth for its potential impact on sectors. The seven factors that have more influence, according to the firm, are economic growth, fundamentals, monetary policy, interest rates and inflation, valuations, sentiment and corporate activity.

Here’s how Trump’s policy stances could influence eight sectors: autos, banks, building materials and construction, cryptocurrency, energy, health care, retail and technology.

Automobiles

Monty Rakusen | Digitalvision | Getty Images

The auto sector — like many others — will likely be a mixed bag, experts said.

Trump’s antipathy for electric vehicles is likely to create headwinds for EV producers.

His administration may try to roll back regulations such as a Biden-era tailpipe-emissions rule expected to push broader adoption of EVs and hybrids. He also intends to kill consumer EV tax credits worth up to $7,500 — although states such as California may try to enact their own EV rebates, blunting the impact.

Losing the federal credit would make EVs more costly, driving down sales and perhaps making “per unit economics even less favorable” for automakers, John Murphy, a research analyst at Bank of America Securities, wrote in a Nov. 21 research note.

Some companies seem well-positioned, though: Ford Motor, for example, “has a healthy pipeline of hybrid vehicles as well as traditional [internal combustion engine] vehicles to supplement the EV offerings,” Murphy wrote.

Tariffs and trade conflict pose threats to the auto industry, since the U.S. relies heavily on other nations to manufacture cars and parts, said Callie Cox, chief market strategist at Ritholtz Wealth Management.

They “could affect the cost and availability of cars we see in the U.S. market,” Cox said.

Economists expect tariffs and other Trump policies to be inflationary.

In that case, the Federal Reserve may have to keep interest rates higher for longer than anticipated. Higher borrowing costs may weigh on consumers’ desire or ability to buy cars, Cox said.

However, lower EV production could be a boon for companies that manufacture traditional gasoline cars, experts said.

Trump has also called for a “drill, baby, drill” approach to oil production. Greater supply could reduce gas prices, supporting demand for gas vehicles, experts said. But trade wars and sanctions on Iran and Venezuela could have the opposite impact, too.

— Greg Iacurci

Banks

President Donald Trump stands next to JPMorgan Chase CEO Jamie Dimon, left, in the State Dining Room of the White House in Washington, Feb. 3, 2017.

Andrew Harrer | Bloomberg | Getty Images

Trump’s first administration eased certain regulations for banking rules, fintech firms and financial startups.

Likewise, Trump’s second term is expected to usher in lighter financial regulations.

That may help bolster profitability in the sector, and therefore stock prices, said Brian Spinelli, co-chief investment officer at Halbert Hargrove in Long Beach, California, which is No. 54 on the 2024 CNBC FA 100 list.

“The larger banks probably benefit more from that,” Spinelli said.

Less regulation — combined with the prospect that interest rates could stay higher — will provide a net positive for the bank industry, since banks may be able to lend out more risk-based capital, said David Rea, president of Salem Investment Counselors in Winston-Salem, North Carolina, which is No. 8 on the 2024 CNBC FA 100 list.

One issue that emerged this year that could resurface is concern about regional banks’ exposure to commercial real estate, Spinelli said.

“It wasn’t that long ago, and I don’t think those problems disappeared,” Spinelli said. “So you question, is that still looming out there?”

— Lorie Konish

Building materials and construction

Bill Varie | The Image Bank | Getty Images

The housing market has been “frozen” in recent years by high mortgage rates, said Cox, of Ritholtz.

Lower rates would likely be a “catalyst” for housing and associated companies, she said.

However, that may not materialize — quickly, at least — under Trump, she said. If policies such as tariffs, tax cuts and mass deportations stoke inflation, the Federal Reserve may have to keep interest rates higher for longer than anticipated, which would likely prop up mortgage rates and weigh on housing and related sectors, she said.

The whims of the housing market affect retailers, too: Home goods stores may not fare well if people aren’t buying, renovating and decorating new homes, Cox said.

That said, deregulation could be “absolutely huge” for the sector if it accelerates building timelines and reduces costs for developers, Goldberg said.

Trump has called for opening public land to builders and creating tax incentives for homebuyers, without providing much detail.

Housing policy will be “one of the most-watched initiatives coming out of the next administration,” Cox said. “We haven’t gotten a lot of clarity on that front.”

“If we see realistic and well-thought-out policies, you could see real estate stocks and related stocks” such as real estate investment trusts, home improvement retailers and home builders respond well, Cox said.

— Greg Iacurci

Crypto

Republican presidential nominee and former U.S. President Donald Trump gestures at the Bitcoin 2024 event in Nashville, Tennessee, U.S., July 27, 2024.

Kevin Wurm | Reuters

Trump’s election has brought a new bullishness to cryptocurrencies, with bitcoin nearing a new $100,000 benchmark before its recent runup ended.

As president, Trump is expected to embrace crypto more than any of his predecessors.

Notably, he has already launched a crypto platform, World Liberty Financial, that will encourage the use of digital coins.

Those developments come as new ways of investing in crypto have emerged this year, with the January launch of spot bitcoin ETFs, and more recently, the addition of bitcoin ETF options.

Yet financial advisors are hesitant, with only about 2.6% recommending crypto to their clients, an April survey from Cerulli Associates found. Roughly 12.1% said they would be willing to use it or discuss it based on the client’s preference. Still, 58.9% of advisors said they do not expect to ever use cryptocurrency with clients.

“The No. 1 reason why advisors aren’t investing in cryptocurrency on behalf of their clients is they don’t believe it’s suitable for client portfolios,” said Matt Apkarian, associate director in Cerulli’s product development practice.

Even for advisors who do expect they may use crypto at some point, it’s “wait and see,” particularly regarding how the regulatory environment plays out, Apkarian said.

However, investors are showing interest in cryptocurrency, with 90% of advisors receiving questions on the subject, according to research from Christina Lynn, a certified financial planner and practice management consultant at Mariner Wealth Advisors.

For those investors, exchange-traded funds are a good starting place, Lynn said, since there’s less chance of falling victim to one of crypto’s pitfalls such as scams or losing the keys, the unique alphanumeric codes attached to the investments. Because crypto can be more volatile, it’s best not to invest any money you expect you’ll need to pay for near-term goals, she said.

Investors would also be wise to think of cryptocurrency like an alternative investment and limit the allocation to 1% to 5% of their overall portfolio, Lynn said.

“You don’t need to have a lot of this to have it go a long way,” Lynn said.

— Lorie Konish

Energy

President Donald Trump gestures after delivering a speech at a Double Eagle Energy Holdings LLC oil rig in Midland, Texas, July 29, 2020.

Cooper Neill | Bloomberg | Getty Images

As of Nov. 19, energy has been the top-performing sector under President Joe Biden, with a 22.9% gain, even with the administration’s push for renewables and sustainability, according to Raymond James.

Yet it remains to be seen whether that performance can continue under Trump, who has advocated for more oil, gas and coal production. The outlook for the sector could change if Trump acts on a campaign threat to repeal the Inflation Reduction Act, a law enacted under Biden that includes clean energy incentives.

If Trump continues to make it easier to create more oil supply, that might not be a great thing for oil companies, according to Adam, of Raymond James.

“Because there’s more supply, it may tamp down on the price of oil, and that’s one of the biggest drivers of that sector,” Adam said.

Eagle Global Advisors, a Houston-based investment management firm that specializes in energy infrastructure, is “cautiously optimistic” about Trump’s impact on the sector, according to portfolio manager Mike Cerasoli. Eagle Global Advisors is No. 35 on the 2024 CNBC FA 100 list.

“We would say we’re probably more on the optimistic side than the cautious side,” Cerasoli said. “But if we know anything about Trump it’s that he’s a wild card.”

A lot of the Inflation Reduction Act may stay intact, since the top states that benefited financially from the law also handed Trump a victory in the election, according to Cerasoli.

When Biden won in 2020, there was a lot of panic about the outlook for energy, oil and gas. Cerasoli recalls writing in a third-quarter letter that year, “I don’t think it’s going to be as bad as you think.”

Four years later, he has the same message for investors on the outlook for renewables. In the days following Trump’s inauguration, Cerasoli expects there may be a deluge of executive orders.

“Once you get past that, you’ll get a sense of exactly how he’s going to treat energy,” Cerasoli said. “I think people will realize that it’s not the end of the world for renewables.”

— Lorie Konish

Health care

Medicine vials on a production line.

Comezora | Moment | Getty Images

Trump nominated Robert F. Kennedy Jr. as head of the Department of Health and Human Services.

RFK would be a “huge wild card” for the health-care sector if the U.S. Senate were to confirm him, said Goldberg, of Professional Advisory Services.

RFK is a prominent vaccine skeptic, which may bode ill for big vaccine makers such as Merck, Pfizer and Moderna, said David Weinstein, a portfolio manager and senior vice president at Dana Investment Advisors, No. 4 on CNBC’s annual FA 100 ranking.

Cuts to Medicaid and the Affordable Care Act, also known as Obamacare, are also likely on the table to reduce government spending and raise money for a tax-cut package, experts said.

Publicly traded health companies such as Centene, HCA Healthcare and UnitedHealth might be affected by lower volumes of Medicaid patients or consumers who face higher health-care premiums after losing ACA subsidies, for example, Weinstein said.

Robert F. Kennedy Jr. during the UFC 309 event at Madison Square Garden in New York City, Nov. 16, 2024.

Chris Unger | Ufc | Getty Images

Medical tech providers — especially those that supply electronics with semiconductors sourced from China — could be burdened by tariffs, he added.

Conversely, deregulation might help certain pharmaceutical companies such as Thermo Fisher Scientific and Charles River Laboratories, which may benefit from faster approvals from the Food and Drug Administration, Goldberg said.

Vivek Ramaswamy, a former biotech executive whom Trump appointed as co-head of a new advisory panel called the “Department of Government Efficiency,” has called for streamlined drug approvals. But Kennedy has advocated for more oversight.

“There’s a real dichotomy here,” Weinstein said.

“Where do we end up? Maybe where we are right now,” he added.

— Greg Iacurci

Retail

Thomas Barwick | Digitalvision | Getty Images

Tax cuts may boost consumers’ discretionary income, which would be a boon for companies selling consumer electronics, clothes, luxury goods and other items, Goldberg said.

Then again, there’s a “high probability” of tariffs, Weinstein said.

Retailers would likely pass on at least some of that additional cost to consumers, experts said.

All physical goods, from apparel to footwear, tools and appliances are at risk from tariffs, Weinstein said. Tariff impact would depend on how the policies are structured.

Home Depot, Lowe’s and Walmart, for example, source a relatively big chunk of their goods from abroad, Weinstein said.

Home Depot CEO and President Ted Decker said Nov. 12 during the firm’s third-quarter earnings call that the company sources more than half its goods from the U.S. and North America, but “there certainly will be an impact.”

“Whatever happens in tariffs will be an industrywide impact,” Decker said. “It won’t discriminate against different retailers and distributors who are importing goods.”

It’s a good idea for investors to own “high quality” retailers without a lot of debt and with diversified inventory sources, Goldberg said. He cited TJX Companies, which owns stores including TJ Maxx, Marshalls and HomeGoods, as an example.

“Direct imports are a small portion of [its] business and TJX sources from a variety of countries outside of China,” Lorraine Hutchinson, a Bank of America Securities research analyst, wrote in a Nov. 21 note.

Deregulation may be positive for smaller retailers and franchises, which tend to be more sensitive to labor laws and environmental and compliance costs, Goldberg said.

— Greg Iacurci

Technology

Former President Donald J. Trump speaks about filing class-action lawsuits targeting Facebook, Google and Twitter and their CEOs, escalating his long-running battle with the companies following their suspensions of his social media accounts, during a press conference at the Trump National Golf Club in Bedminster, New Jersey, July 07, 2021.

Jabin Botsford | The Washington Post | Getty Images

The technology sector continued its strong run in 2024, thanks in large part to the Magnificent Seven — Amazon, Apple, Alphabet, Meta, Microsoft, Nvidia and Tesla.

Even broadly diversified investors may find it difficult to escape those names, as they are among the top weighted companies in the S&P 500 index.

Information technology — which includes all those stocks except Amazon and Google parent Alphabet — comprises the largest sector in the S&P 500 index, with more than 31%.

Trump is poised to have an influence on looming antitrust issues, amid considerations as to whether Google’s influence on online search should be limited.

Any tariffs put in place may also prompt some sales to decline or the cost of raw materials to go up, said Rea of Salem Investment Counselors.

Nevertheless, Rea said his firm continues to have a “pretty heavy” tech allocation, with strong expectations for generative artificial intelligence. However, the firm does not own Tesla, due to its expensive valuation, and has recently been selling software company Palantir, a winning stock that may have gotten ahead of itself, he said.

Technology valuations are trading well into the high double digits on a price-to-earnings basis, which often signals forward returns will decline, according to Halbert Hargrove’s Spinelli.

Consequently, prospective investors who come in now would basically be buying high, he said.

“If you think you’re going to get the same double-digit returns in the next five years, sure, it could happen on a one-year basis,” Spinelli said. “But your chances historically have been that your returns come down.”

— Lorie Konish

Categories
Technology

This startup's Microliner guarantees a less expensive path to electrical flights

It's been a tough year for air taxi startups. The British company Vertical Aerospace is running out of money, while the German company Lillium is facing bankruptcy. The goals for commercialization continue to expand. Investors are reluctant to get involved.

The reason for all the fighting is pretty simple. Building, certifying and commercializing brand new aircraft designs such as electric vertical takeoff and landing aircraft (eVTOLs) is complex, notoriously expensive and depends on lengthy regulatory processes.

That's partly why German startup Vaeridion is pursuing a simpler, potentially cheaper route to electric flight with an aircraft it calls a “microliner.”

“The Microliner looks like a normal airplane and takes off from a runway – The The only difference is that it runs on batteries,” said Vaeridion’s co-founder and CEO. Ivor van Dartel told TNW. “For operators and passengers, the experience will be essentially the same. Similar to what Tesla did for cars, only for airplanes.”

Webinar: Unicorn DNA: The Blueprint for Scaling Success

What does it take to build a unicorn? Top leaders from unicorn companies reveal the mindset, strategies and innovative thinking that propelled their companies to the top.

Today, Vaeridion announced that it has entered into a Pre Application Contract (PAC) with the European Union Aviation Safety Agency (EASA), marking a major step towards commercial flights.

Think of this contract as a dress rehearsal for aircraft certification. Before a company can officially apply for approval to fly its aircraft (called type certification), this contract allows it to discuss the process with regulators, get feedback on its design and plans, and identify potential hurdles.

EASA's pre-application service was launched last year. Vaeridion said it was the first general aviation manufacturer to win a contract under the program.

Vaeridion's technical manager, Markus Kochs Kämper, called it “a huge milestone” in the development of its Microliner. “This initiative allows us to de-risk our core technology and path to certification of our electric aircraft before submitting a type certificate application,” he told TNW.

Van Dartel and Sebastian Seemann – both former Airbus and ZF engineers – togetherfounded Vaeridion in 2021. Their vision was to build an electric aircraft to replace jet aircraft on short-haul and regional flights.

Preliminary tests put the Microliner's range at around 500 km, the company said. In 2022 aAccordingly, almost a third of flights in the EU covered this distance or less Eurocontrol. And it's twice as much as most eVTOL startups advertise.

From London to Amsterdam? From Berlin to Munich? Madrid to Lisbon? No problem.

Equipped with a single propeller in the nose, the Microliner can achieve this range despite a rather modest charge of batteries housed in the wings for better weight distribution. The aircraft's design was inspired by gliders, whose aerodynamic shape minimizes drag and increases efficiency.

Vaeridion's design is similar to existing regional aircraft, which could reduce development and manufacturing costs compared to more experimental eVTOL models, which often require complicated propulsion systems and vertical lift capabilities.

Vaeridion plans to fly its first prototype in 2027. The company wants this first iteration to be fully compliant with EASA's type certificate requirements. That means it doesn't have to be that way also build an expensive demonstration aircraft. Vaeridion will make a prototype, get it certified and then it will be ready for useThe first commercial flights are planned for 2030.

By leveraging established aviation technologies and infrastructure, Vaeridion's microliner could position itself as a more attainable and scalable option for regional air travel than some of the more extravagant designs on the market. Nonetheless, the company will still need significant funds to fuel its growth, which Van Dartel says is on the horizon – although one should be careful not to spread too much.

Vaeridion plans to build the aircraft from the ground up and sell them directly to customers. The company also expects to generate ongoing revenue through the regular replacement of aircraft batteries. Each upgrade takes advantage of newer battery chemistry, meaning the aircraft's range will increase over time.

With an estimated seat price range between 150 and 300 euros, the Microliner is aimed at business people who want to travel in style and comfort.

Categories
Science

Unexplained heatwave hotspots are popping up all around the world – don't you care?

They are so extreme that they cannot be explained by global warming models!

From the Columbia Climate School and the “Have You Checked the Accuracy and Placement of Thermometers” and “Weather is Not Climate” departments comes this new study that is hilarious in its lameness. It's like these people have never heard of weather and they only exist in the climate headspace. – Anthony

Earth's hottest year was 2023, at 2.12 degrees Fahrenheit above the 20th century average. This exceeded the previous record from 2016. So far, the ten hottest annual average temperatures have been measured in the last decade. And with the hottest summer and hottest single day, 2024 is on track to set another record.

All of this may not be news to everyone, but amidst this rise in average temperatures, a striking new phenomenon is emerging: certain regions are experiencing repeated heatwaves so extreme that they go far beyond what any model of the global economy can predict can predict or explain warming. A new study provides the first global map of such regions, which appear like giant, angry patches of skin on every continent except Antarctica. In recent years, these heat waves have killed tens of thousands of people, destroyed crops and forests, and sparked devastating wildfires.

“The large and unexpected deviations by which recent regional extremes have exceeded previous records have raised questions about the extent to which climate models can provide adequate estimates of the relationships between global average temperature changes and regional climate risks,” the study says.

“This is about extreme trends that are the result of physical interactions that we may not fully understand,” said lead author Kai Kornhuber, an associate scientist at Columbia Climate School's Lamont-Doherty Earth Observatory. “These regions become temporary greenhouses.” Kornhuber is also a senior research scientist at the International Institute for Applied Systems Analysis in Austria.

The study was just published in the journal Proceedings of the National Academy of Sciences.

The study examines heat waves over the past 65 years and identifies areas where extreme heat is accelerating significantly faster than more moderate temperatures. This often results in maximum temperatures that are repeatedly exceeded by excessive, sometimes astonishing values. For example, a nine-day wave that swept across the Pacific Northwest and southwestern Canada in June 2021 broke daily records of 30 degrees Celsius, or 54 degrees Fahrenheit, in some places. This also included the highest temperature ever recorded in Canada, 121.3 degrees Fahrenheit, in Lytton, British Columbia. The next day, the city burned in a wildfire caused in large part by vegetation drying out in the exceptional heat. In Oregon and Washington state, hundreds of people died from heat stroke and other health problems.

Daily maximum temperature anomalies during recent record-breaking heatwaves and their temporal context. (A) Anomaly fields with daily maximum temperature (Tx) of 2 m averaged over the 2021 Pacific Northwest heat wave in North America. Regions where values ​​reached record levels in the specified period (since 1950) are hatched. (B) Time series for 1950 to 2023 of the hottest annual average Tx anomaly in the region indicated by the panel in A (relative to 1981 to 2010, June–August). The record-breaking values ​​of the regional mean Tx and their dates are highlighted in each time series (red dot). (C and D) as A and B, but for the Western European heat wave in July 2022, (E and F) for the heat wave in the Amazon basin in November 2023 (warm season September–November) and (G and H) the heat wave in southern Africa (warm season December–February) in January 2016.

These extreme heat waves have mostly occurred in the last five years or so, although some occurred in the early 2000s or earlier. The hardest-hit regions include populous central China, Japan, Korea, the Arabian Peninsula, eastern Australia and scattered parts of Africa. Others include Canada's Northwest Territories and its High Arctic islands, northern Greenland, the southern end of South America, and isolated parts of Siberia. Areas of Texas and New Mexico appear on the map, but are not at the extreme ends.

According to the report, the strongest and most consistent signal comes from northwestern Europe, where heat wave sequences resulted in about 60,000 deaths in 2022 and 47,000 deaths in 2023. These occurred in Germany, France, the United Kingdom, the Netherlands and other countries. Here, the hottest days of the year have been warming up twice as fast as average summer temperatures in recent years. One reason the region is particularly at risk is that, unlike countries like the United States, few people have air conditioning, as it has traditionally almost never been needed. The outbreaks continued; It was only in September of this year that new maximum temperature records were set in Austria, France, Hungary, Slovenia, Norway and Sweden.

The researchers refer to the statistical trends as “tail broadening” – that is, the anomalous occurrence of temperatures at or beyond the extreme upper end, anything that would be expected with simple upward shifts in mean summer temperatures. But the phenomenon does not occur everywhere; The study shows that maximum temperatures in many other regions are actually lower than models would predict. These include large areas in the northern United States and southern Canada, inland South America, large parts of Siberia, northern Africa and northern Australia. Heat is also increasing in these regions, but the extremes are increasing at a similar or slower rate than average changes suggest.

Rising overall temperatures make heat waves more likely in many cases, but the causes of the extreme heat outbreaks are not entirely clear. In Europe and Russia, a previous study conducted by Kornhuber attributed heat waves and droughts to fluctuations in the jet stream, a fast-moving stream of air that continuously circles the Northern Hemisphere. Bounded by historically freezing temperatures in the far north and much warmer temperatures further south, the jet stream is generally confined to a narrow band. But the Arctic is warming much faster on average than most other parts of the world, and this appears to be destabilizing the jet stream, causing it to develop so-called Rossby waves, which suck in hot air from the south and park it in temperate temperatures Regions that typically do not experience extreme heat for days or weeks.

This is just a hypothesis, and it doesn't seem to explain all the extremes. A study of the deadly 2021 heat wave in Pacific Northwest/Southwest Canada led by Lamont-Doherty doctoral student Samuel Bartusek (also co-author of the latest paper) found a confluence of factors. Some appeared to be related to long-term climate change, others to coincidence. The study identified a disturbance in the jet stream similar to the Rossby waves thought to be affecting Europe and Russia. It also found that decades of slowly rising temperatures had dried out regional vegetation, leaving plants with fewer water reserves to evaporate into the air during a hot spell, a process that helps moderate the heat. A third factor: a series of smaller atmospheric waves that collected heat from the surface of the Pacific Ocean and carried it eastward onto land. As in Europe, few people in this region have air conditioning because it is generally not needed, which is likely driving up the death toll.

The heat wave “was so extreme that it's tempting to call it a 'black swan,' something you can't predict,” Bartusek said. “But there is a line between the completely unpredictable, the plausible and the completely expected that is difficult to categorize. I would describe it more as a gray swan.”

Although the wealthy United States is better prepared than many other places, excessive heat still kills more people than all other weather-related causes combined, including hurricanes, tornadoes and floods. According to a study published last August, the annual mortality rate has more than doubled since 1999, with 2,325 heat-related deaths in 2023. This has recently led to calls for heat waves to be named similarly to hurricanes to increase public awareness and motivation Governments to prepare.

“Due to their unprecedented nature, these heatwaves typically involve a lot have serious impacts on health and can have disastrous consequences for agriculture. Vegetation and infrastructure,” said Kornhuber. “We are not made for them, and we might as well not being able to adapt quickly enough.”

The study was also co-authored by Richard Seager and Mingfang Ting of the Lamont-Doherty Earth Observatory and HJ Schellnhuber of the International Institute for Applied Systems Analysis.

# # #

Like this:

How Load…

Categories
Entertainment

First video look since Well being Scare

Bishop TD Jakes has addressed his recent medical emergency that occurred during a sermon at his church, The Potter's House, in Dallas, Texas. The incident, which caused concern, showed Bishop Jakes beginning to twitch on stage, as seen in a video previously shared by The Shade Room.

RELATED: Prayers up! Bishop TD Jakes' church issues statement following his medical emergency in Dallas

Bishop TD Jakes speaks about medical emergency

In his first video message since the horror, Bishop Jakes delivered an emotional message, thanking everyone for their overwhelming prayers and support during this time. The video shows Bishop Jakes in a wheelchair leaving what appears to be a hospital. He wore an olive green cap, a cream hoodie and light green pants.

As he tries to get up from the wheelchair, Jakes says: “He’s so grateful to be here.” He then thanks him “Medical professionals, everyone who texted, prayed, held vigils, and those who sent love and notes.” Fighting back tears, he says, “Thank you,” and admits that “it didn't have to happen this way.” Bishop Jakes also reflected on “not being afraid to die.” But he admitted that he did not want to harm his children, his loved ones or his church, emphasizing: “You still need him.”

Social media reactions

The Roommates immediately flooded The Shade Room's comments section with reactions to Bishop TD Jakes' health update. Many were happy to see him in good spirits and continued to send him prayers.

Instagram user @mariahpowell___ wrote: We love you, Bishop.”

Instagram user @tuddiengeemomma wrote: Luvvv him…thank God he’s okay.”

While Instagram users @therootdoctor wrote:We are grateful that you are here with us, Bishop. Rest and recover. ”

Then Instagram user @omalicha_angelina wrote:We love you, Bishop! I’m glad you’re home for the holidays!”

Another Instagram user @ava.woods1990 wrote: I grew up with him in our household, speedy recovery Bishop.”

Finally, Instagram user @landlord.mocha wrote: 'my eternal bishop 🤍”

More information about what happened to Bishop Jakes

As TSR previously reported, concerns were raised about Bishop TD Jakes after a viral clip from his service at the Potter's House in Dallas on Sunday. The clip shows him experiencing a medical emergency on stage. After the video spread on social media, The Potter's House thanked and confirmed supporters in an Instagram post Bishop Jakes was in stable condition.

“During today’s service, Bishop TD Jakes suffered a minor health incident and received immediate medical attention following his powerful hour-long message. Bishop Jakes is stable and is being cared for by medical professionals. The entire Potter's House family is grateful for the love, prayers and support of the community. Thank you for your understanding and continued prayers,” the official statement said.

Jakes' daughter, Sarah Jakes Robertstogether with her husband, Toure Robertsalso addressed the situation by sharing an update on his health. In an Instagram video, Sarah and Touré assured everyone that Bishop Jakes was recovering well, staying strong and receiving medical attention following the incident.

RELATED: TD Jakes' daughter Sarah speaks out after his medical emergency during a church service

What do you think, roommates?

Categories
Sport

Liverpool stays excellent in Europe whereas the distress in Madrid continues

November 27, 2024, 5:50 p.m. ET

LIVERPOOL, England (AP) — Liverpool continued its 100 percent start to the UEFA Champions League with a 2-0 win over Real Madrid on Wednesday, putting the reigning European champions in danger of missing out on qualifying for the knockout stages .

Second-half goals from Alexis Mac Allister and Cody Gakpo at Anfield sealed Liverpool's fifth straight Champions League win and moved Arne Slot's team two points clear at the top of the table. It was the Reds' first win over Los Blancos in the Champions League since March 3, 2009, ending an eight-game winning streak against the Spanish capital club (a span of seven defeats).

But Real, who won the Champions League for the 15th time against Borussia Dortmund at Wembley last season, have lost three of five games so far and are in 24th place – the final qualifying spot for the playoff phase in February.

Kylian Mbappé had a chance to equalize for Madrid when he saved a penalty from Liverpool goalkeeper Caoimhín Kelleher as the home team made it 1-0. The penalty drama also hit Liverpool when Mohamed Salah missed his spot kick in the 70th minute.

Editor's Tips

2 relatives

Real now face a tough game against UEFA Europa League champions Atalanta on matchday six next month as they look to boost their hopes of qualifying for the next stage of the competition. – Mark Ogden

Mbappé and Salah both miss, Mbappé's goal is costly

No one will have been more pleased to see Salah send his second-half penalty wide at Anfield than Mbappé, who saw his own spot-kick saved nine minutes earlier. Salah's miss took at least some of the attention away from Mbappé after a truly disastrous evening for the Madrid striker.

After a rocky start to life at the Bernabeú, this was the France international's biggest opportunity yet to impress in a Madrid shirt. Instead, it was his season so far in microcosm. In 90 minutes, Mbappé only had two shots, one on goal, and that was the penalty. He attempted just 22 passes – only Ferland Mendy had fewer – and completed 16 of them.

The penalty could have changed his evening and Madrid would have been right back in the game with the score at 1-1. Instead, Mbappé falsified his text. His performance will be scrutinized in the Madrid media on Thursday and fans' patience won't last forever.

Salah's miss was less costly – even if it was a worse attempt – and could soon be forgotten in light of Liverpool's victory. But it wasn't what he needed either, the week he admitted he was “more out than in” at Anfield having not received a new contract offer.

However, Salah is a Liverpool legend and his team has enjoyed success both domestically and in Europe. Mbappé is just starting in Madrid and with three out of five defeats, the Champions League season is already getting out of control. –Alex Kirkland

Liverpool's perfect start to the Champions League season continued on Wednesday, defeating Real Madrid at Anfield. Robbie Jay Barratt – AMA/Getty Images

Kelleher lives up to Klopp's nickname

If Kelleher's Liverpool career so far could be summed up in a single moment, perhaps it would be his superb penalty against Mbappé.

The man who Jürgen Klopp once described as “the best No. 2 in the world” and who remained uninvolved for most of the evening against Madrid, once again lived up to his title and became the first goalkeeper to beat the French in the Champions League They laid the foundations for Liverpool to claim a famous victory against their European nemesis.

In fact, Kelleher can no longer be considered “No. 2”. The Brazilian's ongoing problems with a hamstring injury have seen him play more times for Liverpool than Alisson Becker in 2024.

He didn't let the Slot team down on Wednesday evening either and saved the hosts' clean slate with a few last-minute saves. While the impending arrival of Giorgi Mamardashvili from Valencia certainly means that Kelleher's long-term future lies away from Anfield, his continued brilliance in Alisson's absence means that if or when he does depart, he will do so as a cult hero. – Beth Lindop

STREAM ESPN FC DAILY ON ESPN+

Dan Thomas is joined by Craig Burley, Shaka Hislop and more to bring you the latest highlights and discuss the biggest storylines. Stream on ESPN+ (US only).

Bradley gives Alexander-Arnold a look into the future

Trent Alexander-Arnold may have had an uncomfortable glimpse of the future as he sat on the Liverpool substitutes' bench as his team-mates beat Real Madrid.

On the one hand, the Liverpool full-back will have seen Conor Bradley put in an impressive performance at right-back, showing he is more than capable of keeping Alexander-Arnold out of the team once he is fully fit. And with endless speculation linking Alexander-Arnold with a free agent move to Real next summer if he doesn't sign a new contract at Anfield, the 26-year-old may have just learned that the La Liga Giants are a team just six months into relegation months after winning the Champions League and that a move to the Santiago Bernabeú may not be the dream it once seemed.

However, this evening was really all about Bradley, the impressive 21-year-old who was outstanding against Real.

The Northern Ireland international set the tone with a tough tackle on Mbappé in the first half, which drew huge celebrations from The Kop. As a full-back, he continued to deliver a rock-solid performance and also posed a threat on offense.

Bradley only failed to score when Thibaut Courtois parried his close-range header with a world-class save in the second half.

If Liverpool are afraid of losing Alexander-Arnold, that really shouldn't be the case. –Ogden

Conor Bradley's performances at right-back caused a stir among the Anfield crowd against Madrid on Wednesday. Richard Callis/Eurasia Sport Images/Getty Images

Bellingham feels Anfield's wrath

Jude Bellingham gave a blunt press conference before that game in which he spoke of being made a “scapegoat” after England failed to win Euro 2024. He also dismissed speculation that he almost moved to Liverpool before joining Real Madrid in 2023 because Real was on a “different level”.

Bellingham's comments about Liverpool resulted in him being booed by the Anfield crowd every time he touched the ball. It seemed to have an impact on his performance as the 21-year-old was weak against Slot's side.

Liverpool midfielders Mac Allister and Ryan Gravenberch dominated Bellingham, both in physical challenges and with the ball, and he spent most of the game trying to make an impact.

In Bellingham's defense, he played a deeper role than he normally enjoys. Carlo Ancelotti deployed him in the left midfield behind the three of Mbappé, Brahim Díaz and Arda Güler.

But just like England at Euro 2024, when the game passes him by, Bellingham offers little and his frustration becomes clear. This game was another example, and it couldn't have been worse timed considering Bellingham had complained about his treatment after the Euros.

When a player talks about being misjudged or treated harshly, the best way to prove his point is usually on the field. At Anfield he was eventually overshadowed by two of the players Liverpool recruited after they withdrew from the race to sign him 18 months ago. –Ogden

Categories
Health

Amgen says weight problems drug MariTide induced as much as 20% weight reduction after one 12 months

The Amgen logo is displayed in front of the Amgen headquarters in Thousand Oaks, California on May 17, 2023.

Mario Tama | Getty Images

Amgen said Tuesday its experimental weight-loss injection helped patients with obesity lose up to 20% of their weight on average after a year in a critical mid-stage trial, as the company fights to break into the booming obesity drug market to get in.

The drug MariTide also helped patients with obesity and type 2 diabetes lose up to 17% of their weight after one year. The company said it did not observe a plateau in any of the patient groups, indicating the possibility of further weight loss beyond week 52. MariTide was taken monthly or even less frequently in the study – which could offer an advantage over the popular weekly injections on the market.

But Amgen shares fell about 5% on Tuesday as results appeared to be at the low end of Wall Street's lofty expectations for the drug. Ahead of the data release, several analysts said they wanted MariTide to show at least 20% weight loss in the Phase 2 trial, with some hoping for as much as 25%.

Wall Street has been eagerly awaiting the results of the study, which will shed light on how Amgen's drug competes with blockbuster weight-loss injections Novo Nordisk And Eli Lilly and a crowded field of treatments being developed by other drugmakers.

Jared Holz, healthcare equity strategist at Mizuho, ​​said in an email Tuesday: “We feel investors have even more confidence in Eli Lilly and Novo Nordisk as leaders in the weight loss drug market.” He noted that Amgen could potentially be a “distant third/fourth player” in this space, as MariTide likely won't come to market until around 2027.

Amgen only released data on the first of two yearlong parts of the study, which tested different dose sizes, schedules and treatment regimens of MariTide. The main goal of the study was to measure the extent of weight loss, but it also looked at how long participants could go between injections and still lose pounds.

Specifically, Amgen said patients who received the highest dose of MariTide every two months experienced comparable weight loss to those who took it monthly, suggesting the possibility of less frequent dosing of the drug.

Approximately 11% of patients in the study discontinued treatment due to adverse side effects, while less than 8% discontinued treatment specifically due to gastrointestinal side effects. Gastrointestinal side effects were predominantly mild to moderate and were primarily related to the first dose of the drug.

Amgen said dose escalation, in which patients start with a lower dose of MariTide and gradually increase it until they reach a higher target dose, significantly improved the frequency of these side effects in the study.

“Based on this data, we believe MariTide has a unique, differentiated and competitive profile that we will explore in the third phase of development,” Amgen CEO Robert Bradway said on a post-earnings call with investors on Tuesday.

More CNBC Health coverage

The company will use the results of the first part to “determine the fine details” of the design of its late-stage trial of the treatment, which is “already deep in planning,” Amgen Chief Scientific Officer Jay Bradner said earlier in a statement Interview this month.

Amgen said MariTide could provide faster weight loss, potentially better weight maintenance and fewer injections than weekly injections such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. That could boost Amgen's chances of capturing a slice of the weight-loss drug market, which some analysts predict could be worth $150 billion a year by the early 2030s.

Later studies of Wegovy showed that it resulted in 15% weight loss within 68 weeks, while Zepbound helped patients lose more than 22% of their weight within 72 weeks.

MariTide offers a new approach to weight loss compared to drugs already on the market because it is a so-called peptide-antibody conjugate, which is a monoclonal antibody bound to two peptides. The peptides activate receptors of a gut hormone called GLP-1, while the antibody blocks receptors of another hormone called GIP hormone.

This is different than Eli Lilly's obesity drug Zepbound, which activates both GIP and GLP-1. Wegovy activates GLP-1 but does not target GIP, which can also affect how the body breaks down sugar and fat.

“MariTide's synergistic molecular design requires only a fraction of the peptide supply with fewer injections and fewer devices compared to weekly injectable alternatives,” Bradner said on Tuesday's conference call.

Amgen shares have risen this year in anticipation of midterm study data. That rally lost steam in recent weeks when an analyst raised questions about MariTide's possible side effects related to bone density. Amgen has stated that it has no concerns about MariTide's bone density data.

Experimental design

The first part of the phase 2 study examined 592 patients, including 465 patients with obesity and 127 patients with obesity and type 2 diabetes. The study examined MariTide in 11 different patient groups, with researchers testing different treatment regimens and dosage levels – 140, 280 and 420 milligrams.

For example, some groups used rapid dose escalation, in which patients were started on a lower dose of MariTide and gradually increased over four weeks until they reached a higher target dose. Others experienced a slower dose increase over 12 weeks.

Several groups took MariTide once a month, while one group took the highest dose of the drug every two months. In an interview, Bradner pointed out that patients with type 2 diabetes “are known to respond less favorably to weight loss medications,” which is why Amgen did not assign them to a group that used dose escalations or less frequent dosing schedules.

More than 90% of eligible patients agreed to participate in the second part of the study, which will examine how durable MariTide's weight loss is. The company is “interested in seeing how quickly people who have lost weight regain their strength after stopping the medication,” Bradner said in the interview.

The second part of the study will also assess progressive weight loss after the first year of taking MariTide and test even more infrequent dosing of the drug. Amgen has not said when it will release data from the second part of the trial.

Patients who continued the study were randomly divided into several groups.

For example, patients who took 140-milligram doses of MariTide in the first part of the study will either continue taking that dose or switch to a placebo for another year, which will measure how long MariTide weight loss lasts. Some people who took 280-milligram doses in the first part of the study will take lower doses of the drug for a year.

Amgen is also testing a quarterly schedule in some patients who took 420-milligram doses in the first part of the study. This means that patients receive a vaccination every 12 weeks.

Don't miss these insights from CNBC PRO

Categories
Technology

Teslas in all probability gained't get California's new electrical car tax rebate

California appears eager to reassert itself, not only as one of the world's largest economies, but also one where electric vehicles will continue to thrive.

Gov. Gavin Newsom has announced that California will seek to revive state tax rebates for electric vehicles if the new Trump administration follows through on plans to end the existing $7,500 federal incentive for electric vehicles.

“Consumers continue to prove skeptics wrong – zero-emission vehicles are here to stay,” Newsom said in a statement. “We will step in if the Trump administration eliminates the federal tax credit, redoubling our commitment to clean air and green jobs in California.”

The governor's office reportedly added that the state's electric vehicle incentive would likely exclude Tesla and some other automakers in an effort to promote market competition and innovation in the state.

Tesla CEO Elon Musk, a close adviser to President-elect Donald Trump, has given his blessing to eliminating federal incentives for electric vehicles, saying the move would likely be “devastating” for Tesla competitors but would have little impact on his company would.

Musk tweeted on X, the social media platform he owns, saying California's plan to exclude his company from electric vehicle rebates was “crazy.”

California, the largest economy in the U.S. and the fifth largest in the world, recently surpassed the 2 million mark in electric, plug-in hybrid and hydrogen-powered vehicles sold statewide.

Many analysts believe that eliminating federal incentives would lead to a collapse in U.S. electric vehicle sales. Some predict this would result in an immediate 27% drop in demand for electric vehicles.

The Zero Emission Transportation Association (ZETA), a trade group with members including Tesla, Waymo, Rivian and Uber, has also advocated maintaining government incentives for the production and sales of electric vehicles.

The incentives have helped domestic manufacturers of electric vehicles and their components such as batteries increase job opportunities across the U.S., including in many Republican-dominated states such as Ohio, Kentucky, Michigan and Georgia, the group says.



Categories
Science

An extremely high-resolution picture of the solar

Our local star, the Sun, has been the source of many studies, from ground-based telescopes to space-based observatories. The ESA Solar Orbiter approaches the Sun, capturing images in unprecedented detail. In March last year it reached the halfway point and captured a series of 25 images. They have now been put together to create an image with an astonishingly high resolution. You can even zoom in to see individual grains in the solar photosphere.

Compared to Earth, the Sun is massive, but compared to other stars it is pretty average. It provides energy to sustain life through the process of nuclear fusion deep in its core. The hydrogen atoms are fused into helium and produce so much energy that heat and light flood our planet. Like all other stars, the Sun is a large ball of electrically charged gas with an apparent surface temperature of about 5,500 °C. It measures an incredible 1.39 million kilometers in diameter and is an average of 150 million kilometers away from us. It makes up 99% of the solar system's mass and is responsible for its immense gravitational pull, which has kept planets, asteroids and comets in their orbit for the last 4.6 billion years!

The Sun on November 1, 2023 with Unistellar's eQuinox 2 telescope and Smart Solar Filter. Photo credit: Nancy Atkinson.

Without a doubt, it is the most prominent astronomical object to grace our skies, and so it is no surprise that it has been the target of many, many studies. ESA's Solar Orbiter is one of those space-based observatories that has begun to reveal some of the secrets of our nearest star. Launched in February 2020, it was intended to capture images of the Sun's poles and measure its magnetic fields and solar wind. The Solar Orbiter's orbit is very specific and follows an elliptical orbit that brings it within 42 million km of the Sun.

Solar orbiter

There are instruments on board Solar Orbiter to study the dynamics of the Sun. The most exciting of these are those designed for direct observation of the Sun, which include the Extreme Ultraviolet Imager (EUI) and the Polarimetric and Helioseismic Imager (PHI), which, in combination with other instruments on board, produce some incredibly high resolution images can generate. With Solar Orbiter already halfway to the Sun, ESA has released a stunning new image of our nearest star, based on data from EUI and PHI.

At the time the images were taken, Solar Orbiter was 74 million km from the Sun (Mercury is about 50 million km away), too close to capture a single image of the entire Sun. Instead, 25 images were taken within a few hours and then assembled into the mosaic that has just been published. The finished result can be seen here and has a resolution of around 175 km per pixel. Previous observations went deeper, for example the Gregor Solar Telescope on Tenerife achieved a resolution of just 50 km per pixel, but only for a small section of the sun.

Large mosaics were never possible because the turbulence in the atmosphere made it impossible to stitch together enough images. The picture is breathtaking. If you zoom in, you can see the granulation pattern throughout the sun's photosphere and even some sunspots in super-high resolution.

Source: The Sunfire Up Close

Like this:

How Load…

Categories
Technology

Air taxi startup Vertical Aerospace is increasing the runway with a $50 million lifeline

Vertical Aerospace has been given a crucial lifeline to stave off potential bankruptcy for the financially troubled flying taxi startup.

The UK based company – which manufactures electric vertical take-off and landing (eVTOL) aircraft – secured the fresh funds from its largest creditor, the American debt investor Mudrick Capital.

The agreement announced Monday includes a $50 million cash injection and a large debt-to-equity swap. Mudrick will invest $25 million upfront and guarantee an additional $25 million in future funding, offset by contributions from third-party investors.

Mudrick will also convert half of its $130 million in outstanding debt into equity at $2.75 per share, increasing its ownership interest in Vertical to just over 70%. This move reduces Vertical's debt burden while extending the repayment date for the remaining $65 million to December 2028.

The 💜 of EU technology

The latest rumors from the EU tech scene, a story from our wise old founder Boris and questionable AI art. It's free in your inbox every week. Register now!

Vertical founder Stephen Fitzpatrick, whose stake will shrink from 70% to around 20%, is stepping away from an operational role. He will remain on the board as a non-executive director. Despite the shift in control, Vertical will continue to operate from its headquarters in Bristol.

“The additional equity capital and stronger balance sheet will allow us to fund the next phase of our development program and fulfill our mission to bring this amazing electric aircraft to the skies,” Fitzpatrick said.

The rescue deal comes at a crucial time for Vertical, which has wasted money trying to get its VX4 aircraft tested, certified and airborne by 2028.

In September, Bloomberg reported The without With additional funding, Vertical risks running out of money by March 2025. Stuart Simpson, the startup's chief executive, said Mudrick's new backing will now extend its liquidity until the end of 2025.

eVTOL startups have attracted huge investments in recent years, driven by the promise of revolutionizing urban transport through quiet, environmentally friendly flights. Optimism – and some hype – fueled early funding, but many underestimated the challenges of developing, certifying and scaling production.

As costs rose and Schedules slippedInvestors' confidence steadily dwindled, leaving many start-ups on the ground. One of Vertical's main competitors, the German startup Lilium, filed for bankruptcy this month after failing to raise new funds.

Vertical, which went public on the New York Stock Exchange in 2021, has lost 95% of its market value since listing. While the bailout gives the company a lifeline for now, its future is far from certain.

Categories
Health

Trump's FDA decide for Makary may very well be a aid for biotech and pharma

Dr. Marty Makary on December 12, 2018 in New York City.

Noam Galai | Getty Images

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health news straight to your inbox. Subscribe here to receive future editions.

Happy Tuesday! President-elect Donald Trump's decision to lead the Food and Drug Administration appears to allay fears that there could be significant disruption in the biotech and pharmaceutical industries over the next four years.

Trump on Friday called Dr. Marty Makary, a pancreatic surgeon at Johns Hopkins University, was named FDA commissioner. If confirmed by the Senate, Makary would be responsible for regulating food, thousands of vaccines and other drugs, medical devices and tobacco products.

He would respond to Trump's more controversial choice to head the Department of Health and Human Services, Robert F. Kennedy Jr., a prominent vaccine skeptic and former environmental lawyer who also needs Senate confirmation.

Both Kennedy and Makary have openly criticized federal health officials, and both have recently criticized the government for not prioritizing chronic diseases.

But unlike Kennedy, Makary comes from a more traditional health care background as an experienced physician. Makary is also an executive at telehealth company Sesame, which connects consumers with doctors who can prescribe compounded versions of popular weight-loss medications.

Makary will likely take a “more sensible approach than has been feared” in leading the FDA, BMO Capital Markets analyst Evan Seigerman wrote in a note on Sunday, adding that Makary “is good across the entire continuum of U.S. health care appears to be informed and supportive of an evidence-based medical intervention.”

“All in all, we believe the FDA's election could provide a reprieve for BioPharma investors, removing uncertainty and reversing significant declines in the week RFK Jr. was named head of HHS,” Seigerman said .

Some health experts and investors feared that Trump would choose someone to lead the FDA who lacked sufficient medical background and could politicize the drug regulatory process at the agency, jeopardizing the approval of new products and innovations in general.

“We expect Makary to promote technology/innovation in a way that provides some relief to those who do so.” [are] “I worry about a department becoming more focused on different virtues,” Jared Holz, health equity strategist at Mizuho, ​​said in an email last week.

He added that Makary's “familiarity with the [healthcare] Industry that we believe gets a lot of attention.”

So how does Makary feel about health in the U.S.?

Makary has long challenged the U.S. medical establishment by researching and publishing books about the high cost of health care, the lack of transparency in medicine and medical errors.

Makary does not appear to hold the same anti-vaxxer views as Kennedy, but has recently made statements expressing support for Kennedy's “Make America Healthy Again Platform.” Makary said earlier this year: “The biggest perpetrator of misinformation has been the United States government with the food pyramid.”

Makary has been a controversial figure in other ways too, particularly during the Covid-19 pandemic. He somewhat joined traditional public health experts in advocating universal masking and early doses of the vaccines.

But Makary also opposed vaccination mandates and questioned the value of booster shots for children. He also questioned lockdowns, among other tools pushed by public health officials. Additionally, he emerged as a critic of the FDA during the pandemic, criticizing the agency for moving too slowly in approving certain products for Covid.

Seigerman said Markary's support of informed patient choice could lead to a lower hurdle for product approvals. This is likely to be offset by a higher barrier to disclosing a medicine's risks and benefits to patients, as well as higher requirements for monitoring treatments once they have been approved.

“From our point of view, Dr. “Makary’s willingness to be critical of the system, flexible and reasonable in his opinions and support of patient decisions is a positive,” Seigerman said.

But Seigerman noted that he is much more cautious about Trump's choice to lead the Centers for Disease Control and Prevention: Rep. Dave Weldon, a doctor and Republican congressman from Florida. This is due to Weldon's longstanding criticism of vaccinations.

We'll be watching closely to see if Trump's health care picks are confirmed by the Senate. So stay tuned for our coverage.

Feel free to send tips, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.

Latest technology in healthcare: Neuralink approved for new studies, company says

Jonathan Raa | Photo only | Getty Images

Elon Musk's neurotech startup Neuralink announced Monday that it has been approved for a new trial to test whether patients can use a brain implant to control an assistive robotic arm.

Neuralink is developing a brain-computer interface (BCI) that allows paralyzed people to control external devices such as computers and smartphones with their minds. According to Neuralink's website, the company's flagship implant records neural signals using 64 “threads” that are inserted directly into the brain.

Two human patients have so far been implanted with the BCI as part of Neuralink's “PRIME study,” which aims to prove the system is safe and useful. Neuralink's new study, called the CONVOY trial, will examine whether patients can use the same BCI to operate a robotic arm, the company said in a post on X, which is also owned by Musk. Patients can mutually enroll in both studies.

“This is an important first step toward restoring not only digital freedom, but also physical freedom,” Neuralink said in the post.

It is not immediately clear when the trial will begin or how many patients will participate. According to the X post, Neuralink plans to release more information about the study.

The company did not respond to CNBC's request for comment.

Neuralink also announced last week that it had received approval to launch its first international trial in Canada. As with the PRIME trial, the goal of the Canadian trial is to demonstrate the safety and effectiveness of Neuralink's technology, it said in a blog post.

Patients with quadriplegia due to spinal cord injury or a degenerative disease such as amyotrophic lateral sclerosis (ALS) may be eligible to participate, and recruitment is already open, Neuralink said in a post on X.

BCIs have been studied in academia for decades, and competition within the industry has intensified in recent years. In addition to Neuralink, companies such as Synchron, Paradromics and Precision Neuroscience are developing their own BCI systems.

Several of these groups are conducting human trials, but no BCI company has received approval from the U.S. Food and Drug Administration to commercialize their devices.

Feel free to send tips, suggestions, story ideas and data to Ashley at ashley.caroot@nbcuni.com.